{
    "clinical_study": {
        "@rank": "112771", 
        "brief_summary": {
            "textblock": "The primary objective of this program is to provide Daclatasvir in combination with\n      Sofosbuvir with or without ribavirin to subjects with chronic hepatitis C who are at a high\n      risk of liver decompensation or death within 12 months if left untreated and who have no\n      available therapeutic options."
        }, 
        "brief_title": "A Multicenter Compassionate Use Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C", 
        "condition": "Chronic Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Patients chronically infected with Hepatitis C\n\n          -  Patients at a high risk of liver decompensation or death within 12 months if left\n             untreated and who have no available therapeutic options\n\n        Exclusion Criteria:\n\n          -  Patients who are <18 years old\n\n          -  Patients who have contraindications to either Daclatasvir (DCV) or Sofosbuvir (SOF)\n\n          -  Patients who are pregnant\n\n          -  Creatinine clearance (CrCl) \u2264 30 mL/min (as estimated by Cockcroft and Gault formula)\n\n          -  Patients who are pregnant or Women of Child Bearing Potential  who are not using\n             required contraception"
            }, 
            "gender": "Both", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "March 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02097966", 
            "org_study_id": "AI444-237"
        }, 
        "intervention": [
            {
                "intervention_name": "Daclatasvir", 
                "intervention_type": "Drug", 
                "other_name": "BMS-790052"
            }, 
            {
                "intervention_name": "Sofosbuvir", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Ribavirin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ribavirin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 16, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trials Disclosure", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "official_title": "A Multicenter Compassionate Use Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "For Site information please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of email MUST contain NCT# & Site#. Only trial site that are recruiting have contact information at this time"
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Available", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Norway: Norwegian Medicines Agency", 
                "Sweden: Medical Products Agency", 
                "Austria: Agency for Health and Food Safety", 
                "Netherlands: Medicines Evaluation Board (MEB)"
            ]
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02097966"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "N/A", 
        "study_type": "Expanded Access", 
        "verification_date": "April 2014"
    }
}